Hepatitis Drugs

Product Details:

Velpanat is an combination of velpatasvir 100mg+ Sofosbuvir 400mg. Velpanat is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir,a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection with pangenotypic activity.

Dosage and Administration:

Take Velpanat exactly as your healthcare provider tells you to.

• Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): velasof for 12 weeks.
• Patients with decompensated cirrhosis (Child-Pugh B or C): velasof.
• plus weight-based ribavirin with food for 12 weeks
• Weight-based ribavirin dose.
• Less than 75 kg: 1000 mg/day PO divided BID
• ≥75 kg: 1200 mg/day PO divided BID
• Ribavirin starting dose and on-treatment dosage should be modified based on hemoglobin and creatinine clearance
• Dose modification:Severe renal impairment (eGFR less than 30mL/min/1.73 m²) or ESRD: No dosage recommendation can be give owing to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite

 

Side effects:

The most common adverse reactions with velpatasvir were headache and fatigue and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

storage:

Velpanat Store below 30°C (86 ºF).

Brand name : Velpanat

Active Ingeridents : Velpatasvir Sofosbuvir

Company Name : Natco

Package : 28 tablets/bottle

Strength : Velpatasvir 100Mg Sofosbuvir 400Mg

Product Details:

Velasof medication is a combination of sofosbuvir and velpatasvir. This drug work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover.

Sofosbuvir and Velpatasvir is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).

Product Details:

Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).

Therapeutic indications:

Sofosvel is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections

• With or without cirrhosis or with compensated cirrhosis
• With decompensated cirrhosis for use in combination with Ribavirin

Specification:

• Brand Name : Sofosvel
• Generic Name : Sofosbuvir 400mg + Velpatasvir 100 mg
• Formulation : Solid dosage form(Tablet)
• Available pack size : 1×6’s
• Strengths : Sofobuvir 400mg+ Velpatasvir 100m

Product Details:

Velasof is an combination of velpatasvir 100mg+ Sofosbuvir 400mg. Velasof is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir,a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection with pangenotypic activity.

Dosage and Administration:

Take Velasof exactly as your healthcare provider tells you to.

• Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): velasof for 12 weeks.
• Patients with decompensated cirrhosis (Child-Pugh B or C): velasof.
• plus weight-based ribavirin with food for 12 weeks
• Weight-based ribavirin dose.
• Less than 75 kg: 1000 mg/day PO divided BID
• ≥75 kg: 1200 mg/day PO divided BID
• Ribavirin starting dose and on-treatment dosage should be modified based on hemoglobin and creatinine clearance
• Dose modification:Severe renal impairment (eGFR less than 30mL/min/1.73 m²) or ESRD: No dosage recommendation can be give owing to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite

 

Side effects:

The most common adverse reactions with velpatasvir were headache and fatigue and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

storage:

Velasof Store below 30°C (86 ºF).

Brand name : Velasof

Active Ingeridents : Velpatasvir Sofosbuvir

Company Name : Hetero

Package : 28 tablets/bottle

Strength : Velpatasvir 100Mg Sofosbuvir 400Mg

Product Details:

Velpanat is an combination of velpatasvir 100mg+ Sofosbuvir 400mg. Velpanat is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir,a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection with pangenotypic activity.

Dosage and Administration:

Take Velpanat exactly as your healthcare provider tells you to.

• Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Velpanat for 12 weeks.
• Patients with decompensated cirrhosis (Child-Pugh B or C): Velpanat
• plus weight-based ribavirin with food for 12 weeks
• Weight-based ribavirin dose.
• Less than 75 kg: 1000 mg/day PO divided BID
• ≥75 kg: 1200 mg/day PO divided BID
• Ribavirin starting dose and on-treatment dosage should be modified based on hemoglobin and creatinine clearance
• Dose modification:Severe renal impairment (eGFR less than 30mL/min/1.73 m²) or ESRD: No dosage recommendation can be give owing to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite

Brand name : Velpanat

Active Ingeridents : Velpatasvir    Sofosbuvir 

Company Name : Natco

Package : 28 tablets/bottle

Strength : Velpatasvir 100Mg Sofosbuvir 400Mg

We are recognized in the medical industry as a reputed organization, emerged in offering Hepcinat LP Medicine. Our offered medicine is formulated using finest quality chemical compounds and highly developed formulation methodology in compliance with all quality aspects prescribed by the market. To make sure quality and purity of the offered medicine, a team of our quality examiners with hard-earned knowledge in the industry verifies the entire range on different parameters.

Features:

• Accurate composition
• Longer shelf life
• Purity

Other Details:

• We are Leading Supplier and Dropshipper of Medicine Hepcinat LP, Hepcinat and Sofosbuvir.
• Name: HEPCINAT-LP Tablets
• Active Ingredients: Hepcinat LP contains Ledapasvir 90 MG and Sofosbivir 400 Mg.
• Dosage Form: Tablets in bottle.
• Retail Pack: Pack of 28 Tablets
• Company Name: NATCO PHARMA LTD

Additional Information:

• Minimum Order Quantity: 3 Bottle(s)

Keeping in mind the exact needs of clients, we are offering a quality range of Natdac (Daclatasvir 60 mg) - Natco Pharma. The offered medicine is formulated using finest quality pure chemical compounds and superior techniques as per set industry norms. The offered medicine is strictly tested against varied parameters of quality. Used for the treatment of hepatitis C (HCV), we offer this medicine as per the requirements of the customers at market leading prices.

Features:

• Purity
• Precise composition
• Safe to consume

Other Details:

• Natdac 60 mg or Daclatasvir 60 mg is a drug for the treatment of hepatitis C (HCV).
• Daclatasvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is the first-ever approved HCV NS5A replication complex inhibitor, meaning it interferes with a protein the virus uses to reproduce.
• Daclatasvir should be combined with other medications, which may include other direct-acting antivirals that work differently – Sofosbuvir (Hepcinat or Resof).
• Daclatasvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months.

Additional Information:

• Pay Mode Terms: L/C (Letter of Credit),D/A,D/P,T/T (Bank Transfer),Other
• Minimum Order Quantity: 3 Bottle(s)
• Port of Dispatch: Mumbai
• Delivery Time: 10-15 Days
• Packaging Details: 28 tablets in a bottle pack

The major concern with drug interactions exists with medications that are strong inducers of intestinal P-up, such as rifampin and St. John's wort, since these compounds may significantly lower sofosbuvir and GS-331007 levels. 
Additional Detail-

The coadministration of sofosbuvir with the following medications is not recommended because these medications may significantly lower sofosbuvir levels:

• Anticonvulsants: carbamazepine, oxcarbazepine, , and phenytoin
• Antimycobacterials: rifampin, rifapentine
• Herbal Supplements: St. John's wort (Hypericumperforatum)
• HIV Protease Inhibitors: tipranavir-

SoviHep 400mg (Sofosbuvir) is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. Sofosbuvir is a prodrug and after ingestion it is rapidly converted to GS-331007, the predominant circulating drug that accounts for greater than 90% of the systemically active drug. The compound GS-331007 is efficiently taken up by hepatocytes, whereby cellular kinases convert GS-331007 to its pharmacologically active uridine analog 5’-triphosphate form (GS-461203). This triphosphate compound mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in chain termination. The active form GS-461203 targets the NS5B catalytic site and acts as a non-obligate chain terminator. The active compound (GS-461203) does not inhibit host DNA polymerases, RNA polymerases, or mitochondrial RNA polymerase.

SoviHep 400mg is available as a 400 mg tablet. The recommended dose of sofosbuvir is 400 mg taken orally once daily, with or without food. The 400 mg dose of sofosbuvir should be used, regardless of the patient's genotype and prior hepatitis C treatment experience. No dose adjustment is needed for mild-to-moderate renal impairment or with mild, moderate, or severe hepatic impairment. 

SoviHep 400mg has been very well-tolerated in clinical trial. The most common adverse effects observed with sofosbuvir, when used in combination with ribavirin, have been fatigue and headache. Sofosbuvir is pregnancy category B.

The major concern with drug interactions exists with medications that are strong inducers of intestinal P-gp, such as rifampin and St. John's wort, since these compounds may significantly lower sofosbuvir and GS-331007 levels. The coadministration of sofosbuvir with the following medications is not recommended because these medications may significantly lower sofosbuvir levels.

Product Details:

Hepcvir 400mg (Sofosbuvir) is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. Sofosbuvir is a prodrug and after ingestion it is rapidly converted to GS-331007, the predominant circulating drug that accounts for greater than 90% of the systemically active drug. The compound GS-331007 is efficiently taken up by hepatocytes, whereby cellular kinases convert GS-331007 to its pharmacological active uridine analog 5’-triphosphate form (GS-461203). This triphosphate compound mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in chain termination. The active form GS-461203 targets the NS5B catalytic site and acts as a non-obligate chain terminator. The active compound (GS-461203) does not inhibit host DNA polymerases, RNA polymerases, or mitochondrial RNA polymerase.

Hepcvir 400mg is available as a 400 mg tablet. The recommended dose of sofosbuvir is 400 mg taken orally once daily, with or without food. The 400 mg dose of sofosbuvir should be used, regardless of the patient's genotype and prior hepatitis C treatment experience. No dose adjustment is needed for mild-to-moderate renal impairment or with mild, moderate, or severe hepatic impairment.

Hepcvir 400mg has been very well-tolerated in clinical trial. The most common adverse effects observed with sofosbuvir, when used in combination with ribavirin, have been fatigue and headache. Sofosbuvir is pregnancy category B.

Hepcinat 400mg (Sofosbuvir) is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. Sofosbuvir is a prodrug and after ingestion it is rapidly converted to GS-331007, the predominant circulating drug that accounts for greater than 90% of the systemically active drug. The compound GS-331007 is efficiently taken up by hepatocytes, whereby cellular kinases convert GS-331007 to its pharmacologically active uridine analog 5’-triphosphate form (GS-461203). This triphosphate compound mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in chain termination. The active form GS-461203 targets the NS5B catalytic site and acts as a non-obligate chain terminator. The active compound (GS-461203) does not inhibit host DNA polymerases, RNA polymerases, or mitochondrial RNA polymerase.

Hepcinat is available as a 400 mg tablet. The recommended dose of sofosbuvir is 400 mg taken orally once daily, with or without food. The 400 mg dose of sofosbuvir should be used, regardless of the patient's genotype and prior hepatitis C treatment experience. No dose adjustment is needed for mild-to-moderate renal impairment or with mild, moderate, or severe hepatic impairment.

Hepcinat has been very well-tolerated in clinical trial. The most common adverse effects observed with sofosbuvir, when used in combination with ribavirin, have been fatigue and headache. Sofosbuvir is pregnancy category B.

The major concern with drug interactions exists with medications that are strong inducers of intestinal P-gp, such as rifampin and St. John's wort, since these compounds may significantly lower sofosbuvir and GS-331007 levels. The coadministration of sofosbuvir with the following medications is not recommended because these medications may significantly lower sofosbuvir levels:

• Anticonvulsants: carbamazepine, oxycarbazepine, , and phenytoin
• Antimycobacterials: , rifampin, rifapentine
• Herbal Supplements: St. John's wort (Hypericum perforatum)
• HIV Protease Inhibitiors: tipranavir-

Myhep lvir Tablet

 

We are actively Exporter of

Myhep lvir Tablet

.The offered products are provided to our valued clients in various packaging options. These products are highly used for the treatment of hepatitis C. Offered products are developed by utilizing optimum quality ingredients and advanced technology in line with medical industry defined standards. Furthermore, offered products are delivered within committed time limit to ensure clients' production process is not delayed.

Features:

· long shelf life

· Effective

· Highly pure

Ledipasvir

We are actively Exporter of Ledipasvir.The offered products are provided to our valued clients in various packaging options. These products are highly used for the treatment of hepatitis C. Offered products are developed by utilizing optimum quality ingredients and advanced technology in line with medical industry defined standards. Furthermore, offered products are delivered within committed time limit to ensure clients' production process is not delayed.

Features:

· long shelf life

· Effective

· Highly pure

Additional Information:

• Pay Mode Terms: L/C (Letter of Credit),D/A,D/P,T/T (Bank Transfer),Other
• Port of Dispatch: Mumbai
• Delivery Time: 10-15 Days
• Packaging Details: 28 Pills packed in a bottle pack

Our company is actively committed towards offering the most sought range of Resof (Sofosbuvir 400 mg). It is a recommended treatment option in the WHO’s first hepatitis C treatment guidelines. The offered medicine offered by us is extensively appreciated for their zero side effects and exact composition. Offered medicine is formulated from finest quality chemical compounds with industry accepted norms of quality. Provided medicine is tested by quality experts against varied quality parameters to ensure the delivery of flaw free range.

Features:

• Highly effective
• Longer shelf-life
• Purity

Other Details:

• Sofosbuvir, used in combination with other drugs, has been successful to achieve high cure rates at the same time shortening the duration of the treatment to as little as 12 weeks. It is a recommended treatment option in the WHO’s first hepatitis C treatment guidelines.
• Resof will allow a patient suffering from chronic Hepatitis C access to a “more affordable and effective treatment regimen as compared to other drugs.
• Medicine Name: Resof Tablets
• Content: Sofosbuvir
• Strength: 400mg
• Packing: Pack of 28 Tablets
• Form: Tablets
• Manufacturer: Dr. Reddy Laboratories

Additional Information:

• Pay Mode Terms: L/C (Letter of Credit),D/A,D/P,T/T (Bank Transfer),Other
• Minimum Order Quantity: 3 Bottle(s)
• Port of Dispatch: Mumbai
• Delivery Time: 10-15 Days depending on the destination country
• Packaging Details: 28 pills are packed in a bottle

We are actively Exporter of Hepcinat Tablet.The offered products are provided to our valued clients in various packaging options. These products are highly used for the treatment of hepatitis C. Offered products are developed by utilizing optimum quality ingredients and advanced technology in line with medical industry defined standards. Furthermore, offered products are delivered within committed time limit to ensure clients' production process is not delayed.

Features:

· long shelf life

· Effective

· Highly pure

 

 

Additional Information:

• Pay Mode Terms: L/C (Letter of Credit),D/A,D/P,T/T (Bank Transfer),Other
• Port of Dispatch: Mumbai
• Delivery Time: 10-15 Days
• Packaging Details: 28 Tablets are packed in a bottle pack